Banner placeholder

All News

EUSA Pharma Acquires Global Rights to neuroblastoma treatment Isqette® (dinutuximab beta) from Apeiron Biologics

HEMEL HEMPSTEAD, England and VIENNA, Austria – 4 October 2016
EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive global commercialization rights to the oncology product Isqette (dinutuximab beta) from Apeiron Biologics. The immunotherapy has orphan drug designation in the US and EU and is currently under review for marketing authorization by the EMA.
Click here to download the press release (PDF)


EUSA Pharma Announces Acquisition of Global Rights to Next Generation Oncology Supportive Care Product Arcoral® Tab from Arcoral Pharma

HEMEL HEMPSTEAD, England and HOKKSUND, Norway – 12 April 2016
EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of the global rights to a next generation formulation of EUSA’s current Caphosol® product from Arcoral Pharma AS. The product, Arcoral® Tab, which EUSA plans to rebrand under the Caphosol® name, is a topical oral agent used in the treatment of conditions resulting in reduced salivary flow such as xerostomia and hyposalivation caused by radiotherapy, mucositis, surgery, Sjögrens syndrome or obstruction of the salivary glands. Arcoral® Tab is characterized by high concentrations of calcium and phosphate ions, and lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. Arcoral® Tab has the same active ingredients as Caphosol® but comes in the more convenient formulation of an effervescent tablet to produce the mouth rinse.
Click here to download the Press Release (PDF)


EUSA Pharma and AVEO Announce Submission of Marketing Authorization Application for Tivozanib in Advanced Renal Cell Carcinoma

HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. – March 1, 2016
EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC). The filing is based on tivozanib’s existing dataset and follows positive interactions with the Rapporteur and Co-Rapporteur during 2015 which indicated support for a filing using the phase III TIVO-1 trial as the pivotal study. EUSA Pharma submitted the application under the European Union’s centralized procedure, which permits the agency to issue a single marketing authorization that is valid across all EU countries.
Click here to download the Press Release (PDF)


AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe

CAMBRIDGE, Mass. and HEMEL HEMPSTEAD, England – December 21, 2015
AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the treatment of advanced renal cell carcinoma ("RCC"). The agreement also includes a number of additional territories outside North America, including South America and South Africa, and additional potential indications.
Click here to download the Press Release (PDF)


EUSA Pharma Appoints William W Crouse to its Board of Directors

Hemel Hempstead, UK – 9 September 2015
EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with global reach, today announced the appointment of William W Crouse to its Board of Directors.
Click here to download the Press Release (PDF)


EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors

Hemel Hempstead, UK – 21 April 2015
EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göran Ando as a Non-Executive Director. Bryan Morton, who established EUSA Pharma as founder and first CEO, will become Executive Chairman.
Click here to download the Press Release (PDF)


EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business with Global Reach and a Portfolio of Specialty Products Acquired from Jazz Pharmaceuticals.

Hemel Hempstead, UK – 23 March 2015
EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals plc (Jazz).
Click here to download the Press Release (PDF)


Important Information Regarding EUSA Pharma and Jazz Pharmaceuticals

Hemel Hempstead, UK – 20 March 2015
Essex Bidco, a UK company, completed the acquisition of a number of medicines and medical devices from Jazz Pharmaceuticals on 20th March 2015. As part of this acquisition, Essex Bidco Ltd also acquired the EUSA Pharma brand and will trade under this name.
Essex Bidco, trading as EUSA Pharma, now takes responsibility for the following products: Caphosol®; Collatamp®; Custodiol®; Xenazine® and Fomepizole®. In addition EUSA Pharma will manage the Nominative ATU products in France.
All healthcare professionals should be aware that Jazz Pharmaceuticals retains responsibility for the following products: Defitelio® (defibrotide); Erwinase® (asparaginase Erwinia chrysanthemi); Kidrolase. Please consult the Jazz Pharmaceuticals website under “Drug Safety and Medical Information” where contact details are provided for the products and by country.